CDK4 and interstitial lung disease: Recently, on September 13th, 2019, the FDA issued a warning about rare but severe lung inflammation with CDK4/6 inhibitors, based on cases of ILD and pneumonitis identified in the manufacturers’ completed and ongoing clinical trials and the post-marketing safety databases.